LeonaBio (LONA) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
22 Jun, 2026Opening remarks and agenda
Meeting called to order by the Chairperson, with all board members and senior management introduced.
Independent auditor, legal counsel, and Inspector of Election introduced; meeting procedures outlined.
Agenda included voting on proposals as described in the proxy statement dated May 11, 2026.
Board and executive committee updates
Three Class III directors nominated for election to serve until the 2029 Annual Meeting.
All nominees confirmed their willingness to serve if elected.
Shareholder proposals
No shareholder proposals were submitted in accordance with advance notice provisions.
Partial view of Summaries dataset, powered by Quartr API
Latest events from LeonaBio
- Net loss rose to $52.0M as cash fell to $51.1M, with urgent need for additional funding.LONA
Q2 2026 - Virtual annual meeting to vote on directors, auditor, and executive pay, all board-recommended.LONA
Proxy filing - Proxy covers director elections, auditor ratification, compensation, and ESG oversight.LONA
Proxy filing - Q1 2026 net loss rose to $32.9M as R&D spending increased; cash covers 12 months, more funding needed.LONA
Q1 2026 - Lasofoxifene plus abemaciclib shows strong promise for ESR1-mutated metastatic breast cancer.LONA
Status update - Registering 5.5M shares for resale; proceeds from warrant exercise support drug pipeline.LONA
Registration filing - 58.5M shares registered for resale; warrant exercises could yield over $146M for clinical programs.LONA
Registration filing - Secured lasofoxifene license, raised $90M, and advanced clinical pipeline amid higher R&D spend.LONA
Q4 2025 - All proposals, including key share issuances and governance changes, were approved by majority vote.LONA
EGM 2026